Levonorgestrel-Releasing Intrauterine System Lessens Decrease Hysterectomy Rates in Finland

In the treatment of heavy menstrual bleeding, levonorgestrel-releasing intrauterine system (LNG-IUS) or hysterectomy improves equally health related quality of life, but the costs after 5 years are significantly lower in women whose treatment was started with IUS.

The VUOKKO-study was conducted between 1994-2002 in all five University Hospitals in Finland in co-operation with Stakes.

236 women referred for complaints of heavy menstrual bleeding to Finland's five university hospitals were randomly assigned to treatment with LNG-IUS (n=119), or hysterectomy (n=117).

The patients (99%) were monitored for 5 years to compare outcomes, quality of life issues, and costs. The LNG-IUS and hysterectomy groups did not differ substantially in terms of health related quality of life or psychosocial wellbeing (depression, anxiety and sexuality).

Although 42% of the women assigned to the LNG-IUS group eventually underwent hysterectomy, the discounted direct and indirect costs in the LNG-IUS group (US$2,817), remained substantially lower than in the hysterectomy group (US$4660).

Satisfaction with treatment was similar in both groups (more than 90%). Because menorrhagia is often a reason for seeking medical attention, it is important to consider the outcomes and costs of various treatment options to provide the most appropriate care.

By providing improvement in HRQL at relatively low cost, the LNG-IUS offers a wider availability of choices for the patient and decreases costs due to interventions involving surgery. In Finland, the LNG-IUS is widely accepted.

The national hysterectomy rate has declined by about 13% since 1998 suggesting that the use of LNG-IUS is already changing clinical practice.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A Discussion with Hologic’s Tim Simpson on the Future of Cervical Cancer Screening